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A site-directed-mutagenesis study of putative active-site residues
in rat liver betaine–homocysteine S-methyltransferase has been
carried out. Identification of these amino acids was based on data
derived from a structural model of the enzyme. No alterations
in the CD spectra or the gel-filtration chromatography elution
pattern were observed with the mutants, thus suggesting no mod-
ification in the secondary structure content or in the association
state of the proteins. All the mutants obtained showed a reduction
of the enzyme activity, the most dramatic effect being that of
Glu"&*, followed by Tyr(( and Asp#’. Changes in affinity for
INTRODUCTION
Homocysteine (Hcy) represents a key branchpoint in methionine
metabolism [1]. Its synthesis is catalysed by S-adenosylhomo-
cysteine (AdoHcy) hydrolase (EC 3.3.1.1) in a reaction that is
thermodynamically shifted to the production of AdoHcy. This
compound is a potent inhibitor of the transmethylation reactions
dependent on S-adenosylmethionine (AdoMet) [2] and, therefore,
elimination of Hcy has to be carried out, coupled with its
synthesis, to maintain the methylation ratio AdoMet}AdoHcy.
The three enzymes that use Hcy are cystathionine b-synthase
(CBS; EC 4.2.1.22), methionine synthase (EC 2.1.1.13) and
betaine–homocysteine S-methyltransferase (BHMT; EC 2.1.1.5).
CBS initiates the trans-sulphuration pathway leading to cysta-
thionine, which is further used for the synthesis of cysteine [3].
The other two enzymes remethylate Hcy to render methionine in
reactions that use different methyl donors, methyltetrahydro-
folate and betaine. These methyl donors connect the pathway
with folate metabolism and choline oxidation, allowing the
recovery of one of the methylation equivalents used in choline
synthesis, leading to the incorporation of four of its carbon units
into the one-carbon pool [1]. This picture is completed by the fact
that AdoMet, vitamin B
’
and vitamin B
"#
control, directly or
indirectly, the activity of these three enzymes. Alterations in the
Hcy levels reflect changes in any of the reactions mentioned
above. Thus homocystinuria has been related to deficiencies in
CBS and methylene tetrahydrofolate reductase (EC 1.7.99.5).
Moreover, increased plasma levels of Hcy (hyperhomo-
cysteinaemia) have also been detected in patients with cardio-
vascular disease, and this increase is thus considered an
independent risk factor for the development of this type of
illness [4,5].
BHMT is the least studied enzyme of Hcy metabolism. Most
of these enzymes are oligomers, composed of four identical
subunits [6–8], and the one in rat liver contains 407 amino acids
(accession no. AF038870). Its localization is cytosolic and is
Abbreviations used: ADA, adenosine deaminase; AdoHcy, S-adenosylhomocysteine ; AdoMet, S-adenosylmethionine ; BHMT, betaine–homocysteine
S-methyltransferase ; CB-Hcy, S-(d-carboxybutyl)-L-homocysteine ; CBS, cystathionine b-synthase; E21K, Glu21 !Lys mutation; Hcy, homocysteine ; SS,
secondary structure.
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either of the substrates, homocysteine or betaine, were detected
when substitutions were performed of Glu#", Asp#’, Phe(% and
Cys")’. Interestingly, Asp#’, postulated to be involved in homo-
cysteine binding, has a strong effect on affinity for betaine. The
relevance of these results is discussed in the light of very recent
structural data obtained for the human enzyme.
Key words: homocysteine metabolism, kinetic study, methionine
metabolism, site-directed mutagenesis, structural modelling.
restricted to the liver and kidney in most of the species studied
[9,10], but its appearance in lens has also been reported in Rhesus
monkeys [11]. Conservation among mammalian enzymes is very
high, being more than 80% identical at the nucleotide level and
more than 90% at the amino acid level for the rat, human,
mouse and pig liver proteins [12]. This enzyme contains zinc co-
ordinated to three conserved cysteine residues (positions 217, 299
and 300 according to the human sequence) [13,14]. One of the
mutations detected so far in patients with moderate hyperhomo-
cysteinaemia (G199S, Gly"**!Ser) has been suggested to play an
important role in the secondary structure (SS) of the enzyme [15].
Alterations of betaine levels and decreases in BHMT activity have
been observed in choline deficiencies [16], whereas in methionine
deficiencies the enzyme maintains the levels of this essential
amino acid for mammalian growth and development [17]. In
vitamin B
"#
-deficient diets, a decrease in enzyme activity has
been observed [18], whereas increases have been detected in
animals given low-protein diets combined with alcohol, alcohol
liquid diets, high-protein diets or methionine-supplemented diets
[19]. Studies in developing rats have shown that liver activity in
the foetus is lower than that in the adult, a peak being observed
in the first 10 days in the newborn [20]. Expression of BHMT
mRNA is decreased in cirrhotic livers and hepatocellular car-
cinoma [21,22] and is increased in tissue samples from animals on
a methionine-deficient diet [23]. Moreover, cortisol and thyroxine
treatments also affect BHMT activity [20]. Previously, it has been
shown that BHMT regulates the expression of apolipoprotein B,
leading to an increase in related lipoproteins [12], and it has been
located bound to tubulin in liver extracts [24]. On the other hand,
betaine has been proposed to play a role in the protection of
proteins against denaturation in kidney, due to the high level
of urea accumulated in the cells [25], a similar role being ascribed
to the lens BHMT [11].
Finally, structural data on this enzyme are very limited and,
hence, the objective of the present study is to get an insight into
the role of active-site residues. For this purpose, we have built a
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structural model of the rat liver protein and the role of the
proposed active-site amino acids has been tested by site-directed
mutagenesis. The validity of the identification of catalytically
important residues derived from this model has been confirmed
with the report of the first structure of a human BHMT complex
[8] while the present manuscript was in preparation. Therefore
our results are discussed in the light of the data derived from that
X-ray structure.
EXPERIMENTAL
Materials
Betaine, Hcy thiolactone, PMSF, pepstatin A, aprotinin, leupep-
tin, antipain, dithiothreitol, ampicillin, Freund’s adjuvant and
the molecular-mass standards for gel-filtration chromatography
were obtained from Sigma (St. Louis, MO, U.S.A.). [methyl-
"%C]Choline chloride (50–60 mCi}mmol) was supplied by Amer-
sham International (Little Chalfont, Bucks., U.K.). Isopropyl
b-d-thiogalactoside was obtained from AMBION (Austin, TX,
U.S.A.). Superose 12 HR 10}30 was purchased from Amersham
Pharmacia (Uppsala, Sweden). Optiphase HiSafe 3 scintillation
fluid was obtained from E&G Wallac (Milton Keynes, U.K.).
Goat anti-rabbit IgG–horseradish peroxidase, Bio-Rad protein
assay kit I and the electrophoresis reagents were obtained from
Bio-Rad Laboratories (Richmond, CA, U.S.A.). YM-30 ultra-
filtration membranes were purchased from AMICON Corp.
(Beverly, MA, U.S.A.). Chemiluminescence Renaissance re-
agents were obtained from DuPont New England Nuclear
(Boston, MA, U.S.A.). Triton X-100 was purchased from Merck
(Darmstadt, Germany). QuikChange site-directed mutagenesis
kit and the Impact-CN system were supplied by Stratagene (La
Jolla, CA, U.S.A.) and New England Biolabs (Beverly, MA,
U.S.A.) respectively. The rest of the buffers and reagents were of
the best quality commercially available.
Sequence alignments, SS prediction and template searching
The sequence of rat liver BHMT (SwissProt O09171) was used
to search for similar enzymes and to predict the SS. Homologous
proteins have been searched using Psi-BLAST server [26]. Align-
ments between BHMT and other enzyme sequences were made
with the CLUSTAL X program [27] and were corrected manually
when necessary. For SS prediction, three different methods were
used: PHD [28], PSIPRED [29] and JPRED [30]. We considered
secondary elements with a score over six as reliable (nine being
the maximum). All these three methods provided very similar
results.
On initiating the present study, no structure for the BHMT
family of enzymes was available, as revealed by a Psi-BLAST
search. Thus, to find a template for BHMT model building,
different strategies were tried. First, some enzymes with a known
structure and functionally related to BHMT, such as Zn#+-
dependent transferases or methyltransferases, were tested as
possible templates, with no success. Therefore protein-fold
recognition methods were applied using 3D-PSSM [31],
THREADER [32] and BIOINBGU [33] threading algorithms.
Enzymes with good scores by at least two methods were tested as
templates for BHMT homology modelling, and were used to
build a preliminary model when the following criteria were
fulfilled: (1) their SS correlated with BHMT SS prediction, and
(2) some relevant residue conservation was observed.
Homology modelling of the BHMT protein structure
A three-dimensional structure for BHMT has been modelled by
comparative protein modelling methods using the MODELLER
package [34]. This program uses spatial restraints from the input
templates and the model to be built has to satisfy the restraints
as much as possible. Preliminary models were built from an
alignment based on SS correlation between the templates and the
predicted BHMT SS. To consider definitively a protein as a good
template, the cysteines involved in Zn#+ binding had to be
orientated properly in the preliminary models. One of the proteins
tested, adenosine deaminase (ADA), fulfilled all the selection
criteria and, hence, was used as a template (pdb code: 1a4l) [35].
Initially, 15 BHMT models were built, but only the one with the
least restraints violation and the lowest energy was evaluated,
and several cycles of realignment and model building were
repeated until no further optimization of the model was obtained.
The final model was evaluated with VERIFY3D [36] and
PROCHECK [37]. JOY [38] and COMPARER [39] programs
were used to generate structure-based alignments between the
target and the template in every cycle of the model-building
process.
Expression of the fusion protein and purification of rat liver
BHMT
The sequence of rat liver BHMT included in the NdeI–BamHI
sites of the pET11a expression vector [7] was cloned in pBluescript
M13 (›) KS, and later in the NdeI–NotI restriction sites of
pTYB12, to obtain an intein–chitin-binding BHMT fusion pro-
tein. Competent Escherichia coli BL21(DE3) cells were trans-
formed with the plasmid pBHMT-TYB12, and 1 litre of cultures
was grown in Luria–Bertani medium containing 100 lg}ml
ampicillin. Induction was performed for 16 h at 20 °C by adding
0.5 mM isopropyl b-d-thiogalactoside at A
&*&
0.6. Cells were
harvested by centrifugation, washed with water and stored at
fi70 °C until use. Disruption of the cell pellets was performed by
sonication at 4 °C in a Branson 250 sonifier (30 pulses of 30 s
at 30 s intervals, output power level 20) in 10 vol of 20 mM
Tris}HCl (pH 8.0) containing 0.5 M NaCl, 0.1 mM EDTA,
0.1% (v}v) Triton X-100 and protease inhibitors (2 lg}ml apro-
tinin, 1 lg}ml pepstatin A, 0.5 lg}ml leupeptin, 2.5 lg}ml
antipain, 0.1 mM benzamidine and 0.1 mM PMSF). The
soluble fraction was separated by centrifugation for 30 min at
13000 g and loaded on Chitin beads (10 ml) for purification. The
column was washed first with 30 bed volumes of the buffer,
followed by 10 vol of 20 mM Tris}HCl (pH 8.0), containing
50 mM NaCl, 0.1 mM EDTA (buffer A) and 3 vol of buffer A
containing 30 mM 2-mercaptoethanol (buffer B). The column
was incubated for 48 h at room temperature (23 °C) to allow
intein cleavage and eluted with 3 vol of buffer B. The purified
preparation was then dialysed against buffer A (3 litres) to
eliminate a small peptide that originated during cleavage of the
fusion protein. The final purification yield was 4 mg}g of bacteria.
For storage, purified BHMT was added to 50% glycerol and
kept at fi20 °C.
Site-directed mutagenesis
Residues of interest were mutated using the QuikChange site-
directed mutagenesis method, following the manufacturer’s
instructions. Mutants were constructed in the vector pBHMT-
TYB12 using the mutagenic oligonucleotides included in Table 1.
Mutations were verified by sequencing the entire cDNA, using
the dideoxy termination method [40].
Activity and kinetic determinations
BHMT activity was determined for 1 h at 37 °C using the
radioassay described previously [3]. Kinetics for Hcy and betaine
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Table 1 Mutagenic oligonucleotides
The primers synthesized for site-directed mutagenesis are included. Only the sense strand is
shown, and the substitution performed appears underlined.
Mutant Mutagenic oligonucleotide
E21A 5«-GCTTAAATGCTGGCGCAGTCGTGATCGG-3«
E21K 5«-CGCTTAAATGCTGGCAAAGTCGTGATCGG-3«
D26A 5«-GTCGTGATCGGAGCTGGGGGATTTGTC-3«
D26I 5«-GTCGTGATCGGAATTGGGGGATTTGTC-3«
T73G 5«-CGAACGTCATGCAGGGCTTCACTTTCTATGC-3«
F74A 5«-CGAACGTCATGCAGACCGCCACTTTCTATGC-3«
Y77A 5«-GCAGACCTTCACTTTCGCTGCAAGTGAGGAC-3«
A119G 5«-GGATGCATTGGTTGGAGGAGGTGTGAG-3«
E159G 5«-GGACTTCCTCATTGCAGGGTATTTTGAACATG-3«
E159K 5«-GGACTTCCTCATTGCAAAGTATTTTGAACATG-3«
T184G 5«-GCCTATAGCGGCTGGCATGTGCATCGG-3«
C186S 5«-GCGGCTACCATGTCCATCGGACCTG-3«
C186A 5«-GCGGCTACCATGGCCATCGGACCTG-3«
were performed in a concentration range between 1 lM and
6.5 mM at a saturating concentration of either 6.5 mM betaine
or 6.5 mM Hcy.
Determination of SS
Far-UV CD spectra of purified BHMT and mutants were
recorded on a Jasco J-810 spectropolarimeter at 25 °C [41], using
samples of 0.1–0.2 mg}ml protein concentration and 0.1 cm
pathlength cuvettes. After baseline subtraction, the observed
ellipticities were converted into mean residue ellipticities (h
mrw
)
on the basis of a mean molecular mass}residue of 0.110 kDa. SS
composition was calculated using the Jasco software. A minimum
of five spectra were taken for each sample.
Gel-filtration chromatography
Samples of wild-type and mutant BHMT of 100 ll (50 lg)
were injected on a Superose 12 HR 10}30 gel-filtration column
connected to an Advanced Protein Purification System (Waters,
Millipore Corp., Milford, MA, U.S.A.). Equilibration and
elution were performed using 20 mM Tris}HCl (pH 8.0) con-
taining 200 mM NaCl and 0.1 mM EDTA at a flow rate of
0.3 ml}min at 4 °C. Absorbance at 280 nm was recorded and
210 ll fractions were collected to detect the presence of BHMT
by dot-blot. The protein standards used and their elution vol-
umes were as follows: Dextran Blue (2000 kDa), 8.69 ml; apo-
ferritin (443 kDa), 9.87 ml; b-amylase (200 kDa), 11.34 ml;
alcohol dehydrogenase (150 kDa), 12.07 ml; carbonic anhydrase
(29 kDa), 15.12 ml; and ATP (0.551 kDa), 19.26 ml.
Production of a polyclonal anti-BHMT antiserum
Rat liver BHMT purified as described by Gonza! lez et al. [7] was
used to immunize New Zealand rabbits. Preimmune serum was
obtained before injection of the antigen. The immunization
method used was the same as that described previously by our
laboratory [42]. The specificity of the response was tested by
immunoblotting (Figure 1), and the best results were obtained
using a 1:50000 dilution (v}v) of the antiserum.
SDS/PAGE and Western blotting
Denaturing gel electrophoresis of the samples was performed by
SDS}PAGE (10% gel). Staining was performed using Coomassie
Figure 1 Specificity of the anti-BHMT antiserum
BHMT was purified and used for rabbit immunization as described in the Experimental section.
Immune serum was collected and used to test for specificity in Western blot. For this purpose,
10 lg of either purified protein (lane 1) or rat liver cytosol (lane 2) was loaded on SDS/PAGE
gels and transferred to nitrocellulose membranes. The molecular mass of the markers is given
on the right-hand side.
Blue R-250. When needed, a Western blot of the gel was
performed using the buffer system described by Mingorance et
al. [42], and revealed using the anti-BHMT antiserum mentioned
above.
Dot-blot
Samples of the column fractions (maximum volume 50 ll) were
spotted on nitrocellulose membranes. After denaturation using
6 M guanidinium chloride (50 ll), the membrane was washed
twice with TTBS, before the blocking step using low-fat dry milk
(3%, w}v). The membrane was washed again with TTBS and
incubated with a 1:50000 (v}v) solution of the anti-BHMT
polyclonal antiserum prepared in our laboratory. Under these
conditions, the only band detected corresponds to BHMT, as
judged by SDS}PAGE gels (Figure 1). Membranes were revealed
using Renaissance, the exposed films were subjected to densito-
metric scanning and the data were used to elaborate the elution
profile.
Determination of the protein concentration
The protein concentration of the samples was measured either by
using the Bio-Rad kit I, with BSA as a standard, or spectrophoto-
metrically using a calculated molar absorbance coefficient e at
280 nm of 58020 M−" [ cm−" in 6 M guanidinium chloride. This
coefficient calculated from the sequence was corrected appro-
priately for the mutants.
RESULTS AND DISCUSSION
BHMT belongs to the family of thiol}selenol methyltransferases.
Sequence similarity among these enzymes is not high, but a
strong conservation of two motifs, which include the three
cysteine residues involved in zinc binding, is observed. In
addition, SS prediction renders very similar results for all these
proteins (Figure 2). Thus it is believed that all of them may share
a common folding. At the start of the present study, no structure
for this family of proteins was available, except for two domains
# 2003 Biochemical Society
948 B. Gonza! lez and others
Figure 2 Alignment of enzyme sequences belonging to the thiol/selenol methyltransferase family
The alignment includes data from the thiol/selenol methyltransferase family. The highly conserved SS prediction among these proteins is presented as grey-shaded regions (a-helix with white
characters and b-strands with black characters). The a-helices and b-strands comprising the barrel in the human BHMT crystal structure are highlighted below the sequences. As can be observed,
only b2 was not predicted. The conserved residues are marked with an asterisk below the sequence alignment, whereas the residues mutated in the present study are indicated by their sequence
number. Motifs I and II comprising the Zn2+-binding residues (Cys217, Cys299 and Cys300) are boxed, as is the conserved motif TX(ST)(YF)X. Proteins aligned are as follows : rat liver BHMT,
E. coli B12-dependent methionine synthase (MS), S-methylmethionine homocysteine methyltransferase from Arabidopsis thaliana (MHMT) and S-methylmethionine selenocysteine methyltransferase
from Astralagus bisulcatus (MSMT).
of the vitamin B
"#
-dependent methionine synthase that have no
identity with BHMT [43,44]. Consequently, it was necessary
to search for templates among possible structural homologues to
build a model for the BHMT structure. Thus searches were per-
formed based on either functional similarity or fold-recognition
methods, success being achieved only by the use of the latter.
Most of the suggested templates presented the typical TIM barrel
fold, but only those proposed by at least two of the methods
employed were used to build preliminary models. Further
selection was made based on the following criteria : (i) good
correlation between their SS and that predicted for BHMT, (ii)
conservation of catalytically relevant residues in key areas of the
protein and (iii) correct positioning of the cysteines involved in
zinc binding according to the previous data for BHMT [14]. Only
mouse ADA fulfilled these criteria and, hence, was considered
for further analysis.
Mouse ADA belongs to the family of metal-dependent hydro-
lases and catalyses the hydrolysis of adenine to render inosine.
This is a reaction linked to methionine metabolism, since, among
other pathways, adenine can be produced by AdoHcy hydrolysis
in the same reaction that leads to Hcy [45]. Moreover, ADA is a
zinc-dependent metalloenzyme in which the metal assumes the
same role postulated in BHMT, activating a water molecule for
a further nucleophilic attack [35,46,47]. Sequence similarity
between BHMT and ADA is 52%, with only 13% identity.
Their predicted SS correlates well and, in addition, some of the
zinc ligands are conserved (Cys#"( of BHMT aligns with His#"% of
ADA, and both Cys#** and Cys$!! of BHMT align with Asp#*(
of ADA) (Figure 3). The structural model constructed does not
include the 47 N-terminal amino acids. This segment is absent
from many of the members of the thiol}selenol family, suggesting
a non-essential role of this area for the overall folding. The best
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Figure 3 Alignment of mouse ADA and rat liver BHMT used in the construction of the model
SS elements, a-helices and b-strands (grey-shaded regions with white and black characters respectively) of ADA and those built for the BHMT model are shown. The SS elements comprising
the barrel in the human BHMT crystal structure are represented schematically below the sequence alignment. As can be observed, 7 out of 8 b/a blocks were assigned properly in the BHMT
model. Zn2+ ligands identified for both enzymes are boxed.
Figure 4 Structural model for rat liver BHMT
The structural model of BHMT built using mouse ADA as a template revealed an (a/b)8 barrel
as the monomer fold. The main SS elements appear in grey (a-helices) and black (b-strands).
The three cysteine residues involved in Zn2+ binding are represented as ball and sticks, and
the zinc atom was modelled between them.
model obtained is shown in Figure 4. The proposed BHMT
structure is an (a}b)
)
barrel, in which the three cysteines identified
as zinc ligands (Cys#"(, Cys#** and Cys$!!) are pointing to the
centre of the barrel. One of the eight (a}b) blocks comprising
the core of the barrel was not predicted for the thiol}selenol
methyltransferases and was introduced into the model on the
basis of the alignment with ADA. The final model presents only
2.6% of the residues located in disallowed regions according to
a Ramachandran plot, which is an acceptable value for models
constructed using this approach. Evaluation of the model with
VERIFY3D program produces entirely positive scores.
The typical (a}b)
)
barrel fold is one of the largest and most
regular structures described to date. Several features are repeated
in all the proteins folded this way, one of them being the location
of the active site at the centre of the barrel’s cavity. As shown in
Figure 2, b-strands and a-helices are more conserved and form
the barrel’s core, whereas more variability is present in the loops.
Residues involved in catalysis are located in the strands sur-
rounding the cavity, and the loops following the C-terminal ends
of these strands provide the amino acids related to substrate
specificity. In our model, the highly conserved motifs I
[G(LIV)NC#"(] and II (GGCC$!!) [14], containing the zinc-
binding cysteines, are located in loops at the C-terminal ends of
two b-strands in the barrel. Moreover, due to the fact that this
family of enzymes binds zinc and uses Hcy, it is possible to
postulate that the most conserved loops are related to their
binding. Following the same criteria, those areas that are less
preserved, but common among enzymes using the same methyl
donor, could be related to betaine binding. Thus several in-
teresting residues have been identified in our model : Glu#", Asp#’,
Thr($, Phe(%, Tyr((, Ala""*, Glu"&*, Thr")% and Cys")’. Some of
them have been selected due to their correct location at the
C-terminal ends of b-strands in the model. Besides, they are
conserved in all the enzymes of the family (Ala""*, Glu"&* and
Thr")%), align with relevant residues of ADA (Glu#" and Asp#’) or
were proposed to be next to the Zn#+-binding site (Cys")’)
(Figure 3). The rest of the selected residues (Thr($, Phe(% and
Tyr(() are present in a conserved motif, T($X(ST)(YF), which
contains more aromatic amino acids directed to the barrel’s
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Figure 5 CD spectra of wild-type and mutant BHMT
Only CD spectra of wild-type and the most relevant mutants, whose activity is less than 15%
of that of the wild-type, are shown for graphical purposes. ––––, Wild-type ; –––, D26I ; ........,
Y77A ; –*–, E159G ; ––––, E159K. Spectra are the averages of five scans.
Table 2 Comparison of the content of SS elements
Data for the content of the main SS elements obtained from CD spectra are compared with those
derived from prediction methods and X-ray diffraction studies on human BHMT. CD calculation
is within the 10% error due to protein concentration measurements. Predicted and X-ray
diffraction values are based on 360 amino acids, which are those shown in the solved structure.
CD spectra (%) Predicted (%) X-ray diffraction (%)
a-Helix 28.6 34 38
b-Sheet 31.4 7 11
Turns 10.1 20
Random coil 20.9 31
cavity, as required for betaine binding [48]. All these facts make
these residues ideal candidates for further study using site-
directed mutagenesis.
To establish clearly the role of the residues identified in the
structural model, several mutants were prepared (Table 1). For
this purpose, the IMPACT CN system was used, since it allowed
a faster purification to homogeneity of the proteins under study.
In our case, the expression vector of choice was pTYB12, to
protect the BHMT N-terminus from bacterial aminopeptidases.
Cleavage was achieved as described by Breksa and Garrow
[14], leading to a BHMT protein having three extra amino
acids, Ala, Gly and His, at its N-terminus. Addition of
these extra residues did not interfere with either activity or
SS, since the levels of methionine synthesis achieved and the
CD spectra were similar to those obtained from a liver-
purified BHMT (18.7 nmol [min−" [mg−") and a pETT11a
overexpressed BHMT (18.5 nmol [min−" [mg−"). Total and
cytosolic expression levels were similar for wild-type and mutants,
Table 3 Kinetic parameters for BHMT
BHMT activity was measured as described in the Experimental section, for 1 h at 37 °C. Kinetic
studies were performed in the 1 lM to 6.5 mM concentration range for both substrates Hcy
and betaine. Affinities for the substrates in mutants with less than 15% of the wild-type activity
were not determined (n.d.).
Vmax (nmol [min−
1 [mg−1) kcat (s−
1) Km (lM) (Hcy) Km (lM) (Betaine)
Wild-type 18.67‡0.14 0.014 106.4‡11.3 333.3‡25.3
E21A 8.39‡0.25 0.006 17.47‡3.2 138.5‡13.2
E21K 12.82‡0.34 0.009 72.66‡8.9 195.1‡16.87
D26A 6.81‡0.17 0.0051 62.93‡2.6 1174‡102.6
D26I 2.86‡0.67 0.0021 n.d. n.d.
T73G 6.09‡0.2 0.0045 49.25‡7.9 258.4‡17.1
F74A 9.69‡0.26 0.0072 57.44‡7.8 968.6‡99.5
Y77A 1.36‡0.01 0.001 n.d. n.d.
A119G 10.05‡0.3 0.0075 67.98‡9.46 305.6‡29.6
E159G 0.305‡0.02 0.00023 n.d. n.d.
E159K 0.11‡0.025 0.000082 n.d. n.d.
T184G 7.77‡0.6 0.0058 34.46‡13.2 548.1‡55.4
C186S 8.01‡0.26 0.006 74.45‡11.1 206.5‡19.9
C186A 10.12‡0.41 0.0076 24.73‡5.64 185.2‡11.4
as judged by Coomassie Blue staining of SDS}PAGE gels (results
not shown). The purification yield was similar (approx. 4 mg}g
of bacteria), and in addition an anti-BHMT antiserum was able
to recognize all the mutants with similar specificity. Moreover,
the purification procedure was the same for all of the proteins,
suggesting that the BHMT conformation was not significantly
altered in the mutants. Far-UV CD spectroscopy showed no
significant difference among spectra (Figure 5). The content in
main SS elements has been calculated and appears in Table 2.
The composition obtained compares favourably with the values
from prediction methods and with those derived from the X-ray
structure of human BHMT for a-helix content, whereas the
b-sheet percentage resulting from this analysis is overestimated.
This observation concurs with the difficulties in the accurate
assignment of b-sheet structural elements from CD spectra,
which are often rigorously resolved using complementary spec-
troscopies [41,49,50]. In addition, the oligomeric state of the
mutants was also evaluated by gel-filtration chromatography.
No significant change in the elution pattern was observed, the
elution volume corresponding to that of a globular protein with
an estimated molecular mass of 187 kDa. Therefore it can be
inferred that none of the residues studied plays a significant role
in the association of the subunits.
All the mutant proteins exhibited decreased activity (Table 3).
Four groups can be identified, those with approx. 70% of wild-
type activity [E21K (Glu#"!Lys), E21A, C186S, C186A, F74A,
A119G, T73G, T184G], those with an intermediate level (D26A),
those with 15–10% of activity (Y77A, D26I) and finally those
with less than 2% of the original level (E159G, E159K). To get an
insight into the significance of these changes, kinetic studies for
all the mutants within the first three groups were carried out
(Table 3). This type of analysis was not performed for the rest of
the mutants due to the low sensitivity of the assay; however, this
analysis is accurate for BHMT activity determinations [51]. The
K
m
values obtained for the recombinant wild-type protein differed
from those published previously for the rat liver purified BHMT
[52,53], being 9- and 3-fold higher for Hcy and betaine respec-
tively. In fact, the K
m
values obtained for Hcy are closer
to those published for the human liver purified enzyme [54] than to
those for the recombinant humanBHMT [13]. Regarding betaine,
the K
m
values differed markedly from those published for the
human liver enzyme, which are approx. 2.3 mM [13]. Mutant
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proteins E21A, T73G, F74A, C186A and T184G showed in-
creases in affinity for Hcy. Changes of either sign were also
detectable in betaine affinity. Slight increases, approx. 30%,
were observed for E21A, E21K, C186S and C186A. In contrast,
decreases (" 3-fold) were observed for D26A and F74A, the K
m
values reaching the millimolar range as described for human liver
BHMT [13]. Thus, based on these results, it can be inferred that
Asp#’ and Phe(% play a role in betaine binding, since the mutants
generated for these residues show a diminished activity and a
dramatic change in the affinity for this substrate. With respect to
Hcy binding, the strongest effect, a 4–5-fold increase in affinity,
was shown by E21A and C186A. However, the hydroxide-
dependent conversion of Hcy thiolactone into Hcy is not
quantitative [55] and, hence, has a clear effect on the real
concentration of the amino acid in each assay, which is difficult
to estimate. Therefore it could be suggested that Glu#" and Cys")’
may play a role in Hcy binding, but their importance cannot be
directly quantified.
Recently, the structures of human BHMT, Zn#+-depleted and
Zn#+-repleted in complex with a transition-state analogue, S-(d-
carboxybutyl)-l-homocysteine (CB-Hcy), have been published
[8]. The overall fold described for the monomer is an (a,b)
)
barrel,
as proposed in our structural model. Moreover, the complex
with CB-Hcy highlighted the role of some amino acids in the
active site, among them Asp#’, Glu"&* and Tyr(( (numbered
according to the human BHMT sequence). These are the residues
that show important effects on activity in our mutagenesis study
(Table 3). The postulated roles for these residues are related to
Hcy binding (Asp#’), establishing stereospecificity for l-Hcy
(Glu"&*), and interacting with the carboxy group of the methyl
donor (Tyr(() [8]. Activity measurements of the corresponding
mutants revealed strong reductions in methionine synthesis in all
the cases, except for D26A, for which a substantial decrease in
affinity for betaine was detectable, an effect also shown by F74A.
Substitutions performed involving Asp#’ are related to changes
in the charge and the volume of the side chain (a slight decrease in
D26A and an increase in D26I). It is relevant to note that D26A
affects the affinity for betaine, in contrast with the role of Asp#’
in Hcy binding proposed and deduced from its high level of
conservation among the thiol}selenol methyltransferase family
[8]. In the human BHMT crystal structure, Asp#’ interacts with
the backbone amide of Gln(# from b2-strand. This interaction
brings apart the b1- and b2-strands, creating a cleft between
them, which has been proposed to be important in Hcy accommo-
dation. Nevertheless, our results suggest another role for
Asp#’ related to betaine binding. Accordingly, Asp#’ seems to
be involved in shaping the active site, and this role could also be
reflected by changes in activity and the affinity for betaine. An
increase in the K
m
value for betaine was also noticed with F74A,
where a reduction in the length and volume of the side chain is
produced, thus indicating a role for the aromatic ring in betaine
binding. Phe(% precedes Phe(’ and Tyr((, which are involved in
betaine binding, as suggested in the CB-Hcy complex with
human BHMT. In addition, Phe(% is packed against other non-
polar residues, and substitution of phenylalanine by alanine
would break this packing, resulting in a disruption of the local
conformation, and therefore affecting betaine binding.
The results obtained with Glu"&* mutants confirmed the crucial
role of its side chain in BHMT activity, since either of the
substitutions performed (elimination of the side chain or change
of charge in the e group) abolished methionine production.
Moreover, the carboxybutyl moiety of CB-Hcy served to suggest
the binding site for glycinebetaine through its carboxy group, a
role ascribed to Tyr(( of human BHMT [8]. Again, our model
suggested an essential role for this residue, and in fact its
substitution by alanine produced a marked decrease in activity,
thus highlighting the importance of its side chain.
Other residues located close to the Hcy-binding site also show
interesting features when their substitution is carried out. A
conservative change performed on Cys")’, such as that produced
by the inclusion of serine, exerted no effect on substrate affinity.
However, in C186A, when the amino acid chain is shortened and
the -SH or -OH groups disappear, an increase in affinity for Hcy
is detectable, suggesting a role for this residue in substrate
binding. Such a role could not be ascribed in the human crystal
structure, since this is one of the five cysteine residues, considered
non-essential, that were mutated to avoid aggregation [8]. In
addition, mutation of Thr")%, just two residues downstream in
the sequence, also affected Hcy affinity. Thr")% interacts through
its side chain with Asn#"’, which in motif I (GVNC) is involved
in Zn#+ binding. Elimination of the side chain by substitution
with glycine suppressed this interaction and, hence, it could have
an indirect effect on ion binding and therefore on Hcy affinity.
Mutations performed on human Asn#"’ showed a decrease in
activity, which in the case of N216A was comparable with that
produced by T184G, but effects on affinity were not explored
[14].
Finally, all our results indicate that the structural model
presented here shows the main features of the BHMT monomer
and allows the identification of key residues for enzyme activity.
Their importance has been confirmed by site-directed muta-
genesis and kinetic studies, defining a further role for Asp#’ in
the active site. The results obtained are consistent with those
derived from X-ray diffraction, thus suggesting that these types
of structural models can be useful tools for other families of
enzymes with unknown structure, allowing the identification
of key residues involved in catalysis.
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